HeartWare pump approval appears likely, share price up; CoreMedix hit with trading non-compliance notice;

@FierceMedDev: BioMérieux Q1 2012 sales soar, propelled by China, India. Story | Follow @FierceMedDev

> The Nasdaq halted trading of shares of HeartWare International ($HTWR), after indications that the FDA would likely approve the company's implantable heart pump boosted the shares nearly 7%. Story

> CorMedix, ($CRMD) a medical device and pharmaceutical company developing treatments for cardiac and renal dysfunction, has received notice of delisting from NYSE Amex for non-compliance of listing standards. Release

> Toshiba's medical systems division gained FDA clearance for new dose reduction software. Release

> BioLineRx ($BLRX) gained a U.S. patent extension through at least 2029 for a medical device designed to prevent cardiac remodeling after an acute heart attack. The device is out-licensed for development to Ikaria. Release

> Smiths Medical has gained 510(k) clearance in the U.S. to market its new ViaValve Safety IV catheter. Story

Biotech News

@FierceBiotech: The Biggest R&D Spenders In Biopharma. Special Report | Follow @FierceBiotech

@JohnCFierce: AVI's retake on IIb DMD data looks to me like a second attempt at a good first impression. Release | Follow @JohnCFierce

@RyanMFierce: Perakslis: FDA plans to open up some of the FDA's liver tox data on >2000 drugs to outside parties. A good example of data sharing. | Follow @RyanMFierce

> Targacept slashes staff by half in wake of PhIII disaster. News

> The Biggest R&D Spenders in Biopharma. Report

> Scrambling to add new drugs, Big Pharma is paying big premiums for biotechs. Item

> Oregano attacks prostate cancer cells in lab experiment. Article

> Sanofi's Lemtrada beats Rebif in head-to-head MS showdown. Report

> Advocacy groups launch new services to match patients and trials. Story

Pharma News

@FiercePharma: Zyprexa sales fell off a (patent) cliff , but Lilly still beat analyst forecasts for Q1--Reuters. News | Follow @FiercePharma

> GSK scrapes up 2% sales growth despite politics, generics. Article

> Novartis strikes back at production woes with new management. Item

> Spurned GSK chief: We're the 'compelling owner' for HGS. Story

> Amgen joins Big Pharma's branded generics club with $700M deal. News

> Hungry for new drugs, pharma pays big for biotech. Story

Drug Delivery News

@DamianFierce: Tamarisk plans to "turn the industry upside down" with oral insulin platform. News | Follow @DamianFierce

> 'Chemo bomb' nanotechnology effective in halting tumors. Story

> SkyePharma's inhaler takes step toward EMA approval. Article

> Scottish scientists take a page from sci-fi with sonic screwdriver. More

> Australia jumps into life sciences fray with R&D tax credit. Piece

Biomarkers News

> Autism Awareness Month and autism biomarkers. Commentary

> Novo Nordisk, Oxford University seeking inflammation markers. More

> Urine biomarker test for autism on the horizon? Story

> 'Landmark' study splits breast cancer into 10 types. News

And Finally... Medtronic ($MDT) cracked Corporate Responsibility Magazine's top 50 list of America's best corporate citizens. Release

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.